Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Quagen

Drug and asset intelligence for Quagen with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 3
Stage: Development stage unavailable

Recent signals(5)

RegulatoryAugust 9, 2026

FDA Approval Process Update for Glycopyrrolate (ANDA 216910)

The FDA has an active application for Glycopyrrolate (ANDA 216910) submitted by Quagen, currently under standard review.

RegulatoryJuly 27, 2026

FDA Approves Supplement for Valproic Acid by Quagen

The FDA has approved a supplemental application for Valproic Acid submitted by Quagen.

StrategyJuly 19, 2026

FDA Grants Approval for Glycopyrrolate ANDA216910 by Quagen

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Glycopyrrolate submitted by Quagen.

StrategyJuly 12, 2026

FDA Grants Approval for Morphine Sulfate ANDA213892 by Quagen

The FDA has granted approval for ANDA213892, a generic version of Morphine Sulfate submitted by Quagen.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Valproic Acid ANDA090517 by Quagen

The FDA has granted Abbreviated Approval (AP) status for Quagen's ANDA090517 for Valproic Acid.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

— Quagen

July 19, 2026 · N/A

Topline Data

— Quagen

July 12, 2026 · N/A

Topline Data

— Quagen

July 4, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Anticholinergic →

Anticonvulsant →

Antiepileptic →

Neurology · Antiepileptic →

Pain Management →

Pain Management · Opioid →

Respiratory →

Respiratory · Anticholinergic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.